Last reviewed · How we verify
Curium US LLC — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Copper Cu 64 PSMA I&T | Copper Cu 64 PSMA I&T | phase 3 | Radiopharmaceutical; PSMA-targeted theranostic agent | PSMA (Prostate-Specific Membrane Antigen) | Oncology | |
| Abiraterone with Prednisone or Enzalutamide | Abiraterone with Prednisone or Enzalutamide | phase 3 | CYP17A1 inhibitor (abiraterone) + androgen receptor antagonist (enzalutamide) + glucocorticoid (prednisone) | CYP17A1 (abiraterone); androgen receptor (enzalutamide); glucocorticoid receptor (prednisone) | Oncology |
Therapeutic area mix
- Oncology · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Curium US LLC:
- Curium US LLC pipeline updates — RSS
- Curium US LLC pipeline updates — Atom
- Curium US LLC pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Curium US LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/curium-us-llc. Accessed 2026-06-10.